查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840882

miRNA定序与检测市场：依产品类型、技术、应用、最终使用者、工作流程与样本类型划分－全球预测，2025-2032年

miRNA Sequencing & Assay Market by Product Type, Technology, Application, End User, Workflow, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，miRNA 定序和检测市场将成长至 11.2765 亿美元，复合年增长率为 14.55%。

关键市场统计数据
基准年 2024 3.8021亿美元
预计年份：2025年 4.3569亿美元
预测年份 2032 11.2765亿美元
复合年增长率 (%) 14.55%

全面介绍最新的miRNA定序和检测技术，重点阐述其科学潜力以及临床应用转化的挑战。

微型RNA定序和检测技术已迅速从一项小众研究发展成为转化研究和临床开发中分子谱分析策略的核心要素。样本处理、文库建构化学和分析流程的进步提高了小RNA检测的可靠性，而仪器设备的改进则缩短了检测週期，降低了常规应用门槛。因此，包括学术机构、受託研究机构、医院、诊断实验室、製药公司和生物技术公司在内的相关人员，不仅将微小RNA解决方案视为探索性工具，而且将其视为生物标记开发、伴随诊断和标靶治疗发现的候选方案。

儘管取得了这些进展，但该领域仍面临持续的技术挑战，这些挑战决定着技术的应用决策。低起始量、家族成员间的序列相似性以及异构体miRNA的存在，都要求设计高度选择性的检测方法并进行严格的品管。此外，将原始定序资料转化为可操作特征的生物资讯工作流程仍然是关键的区分因素，而可重复的比对、标准化和註释策略则决定了候选miRNA能否实现转化应用。监管和临床检验途径进一步增加了复杂性，凸显了整合检测方法的重要性，这些方法需要将可靠的湿实验方案与检验的计算流程相结合。

从探索性科学到临床效用，需要对检测标准化、实验室间重复性研究以及连接仪器供应商、套件製造商和服务供应商的伙伴关係进行协同投资。在此背景下，可互通的工作流程和与供应商无关的数据格式至关重要，使研究人员和临床医生能够跨平台比较结果，并加速将miRNA讯号转化为诊断和治疗见解。综上所述，当miRNA定序和检测技术以严谨的方法论和与临床目标的策略一致性实施时，它们将成为精准医疗倡议的关键推动因素。

一项关键的变革性转变旨在重塑miRNA测序和检测工作流程，从而实现可扩展的临床转化路径和整合服务模式。

miRNA定序和检测方法的发展正经历着数次变革性的转变，这些转变正在重新定义技术预期和商业策略。次世代定序平台提高了灵敏度和多重分析能力，能够从少量样本同时分析数百种小RNA。同时，检测化学和文库製备技术的改进降低了偏差，提高了定序批次间的一致性，使得不同研究之间的可比性日益增强，并激发了临床研究项目的浓厚兴趣。

同时，RT-qPCR、微阵列和定序技术的融合建构了一个分层诊断生态系统，其中高通量定序发现与使用qRT-PCR检测和微阵列晶片进行标靶验证相辅相成。这种多模态途径支持严格的生物标记合格：发现、正交验证以及在受监管的临床检测环境中的应用。与湿实验室的发展同步，生物资讯学和机器学习演算法也日趋成熟，能够应对小RNA特有的挑战，例如异构体miRNA的检测、序列修剪伪影和跨平台标准化，从而提高最终特征的可靠性。

营运方面的变化也显而易见。服务供应商正在扩展其端到端解决方案的服务范围，将样本物流、定序执行和结果解读相结合；而仪器和试剂製造商则优先考虑能够提高临床实验室易用性的整合工作流程。政策制定者和支付方的讨论日益聚焦于分子生物标记的证据标准，这促使检测方法开发人员、临床实验室和监管机构之间加强合作，以建立验证模板和性能基准。总而言之，这些转变表明，miRNA检测正从实验性工作流程转向精准医疗流程中的标准化组成部分。

重组 miRNA定序和检测业务的供应链策略、采购惯例和韧性计划

近期贸易政策的调整，为依赖进口设备、耗材和试剂的企业采购计画、供应链设计和成本管理带来了更多复杂性。影响进口检测设备和试剂的关税措施大幅增加了许多市场参与企业的到岸成本，促使采购团队重新评估供应商关係、合约条款和库存策略。为此，一些企业正加快步伐，透过供应商多角化和从地理位置较近的製造商采购关键投入品，来减轻跨境政策变化的影响。

这些动态对营运产生了重大影响。科学研究和临床实验室正在调整采购计划，增加关键试剂的储备，并扩大供应商资格资格确认范围，纳入更多国内和区域合作伙伴。製造商和经销商正在探索本地组装、替代物流路线以及重新调整定价模式，以在应对利润压力的同时维持客户供应。营运国际定序中心的服务供应商也在评估生产能力的选址，以及如何调整客户定价以反映新增关税和合规成本。

持续的关税压力往往会促使企业投资区域製造能力和建立策略伙伴关係关係，从而降低对单一供应基地的依赖。同时，采购人员和研发负责人必须权衡供应弹性与替代零件的技术性能之间的利弊。密切注意政策动态，并积极与供应商沟通，了解库存情况、交货前置作业时间和应急计画，对于维持营运连续性以及按时完成miRNA检测开发和临床验证至关重要。

综合考虑产品类型、技术、应用、工作流程、最终用户和样品类型等因素进行市场细分，可为策略投资提供基础。

解读市场需要关注多个细分维度，这些维度共同决定了产品设计、应用路径和使用者需求。根据产品类型，相关人员应评估表达谱检测试剂套件的各种选择，包括微阵列套件、qRT-PCR套件、定序试剂套件、定序平台以及涵盖生物资讯学和定序服务的各种服务。微阵列和 qRT-PCR 试剂套件通常针对特定标靶和临床通量进行最佳化，而定序试剂套件和平台则着重于发现广度和多重定序能力。提供生物资讯学和定序执行服务则弥合了原始资料生成和可操作解读之间的鸿沟。

技术部分重点介绍了微阵列、次世代定序和 RT-qPCR 方法的共存，每种方法在通量、灵敏度和每个样本的成本方面都有不同的平衡：微阵列解决方案对于标准化面板和比较研究仍然很有价值，RT-qPCR 仍然是靶标检验和临床检测确认的主要手段，而次世代定序仪提供全面的发现和发现分辨率的异构体。

临床诊断、疾病研究和药物研发对检测效能、监管文件和长期可重复性都有独特的要求。包括学术机构、受託研究机构)、医院、诊断实验室以及製药和生物技术公司在内的最终用户，各自需要不同的支持：学术团队倾向于开放灵活的探索性研究通讯协定；CRO 重视检测通量和标准化报告；临床实验室优先考虑检验的套件和合规性文件；而行业赞助商则重视与临床试验流程的整合。

透过对工作流程进行细分，所提供的服务分为耗材和服务两部分。耗材包括套件、试剂和实验室器皿，而服务包括数据分析和定序服务。耗材的品质和批次一致性对下游资料的可靠性有显着影响。同时，提供进阶分析的服务对于将复杂的小RNA产量、降解情况和基质效应。

提供可操作的区域洞察，描绘美洲、欧洲、中东和非洲以及亚太地区的创新中心、监管预期和商业现实。

区域动态对创新、临床应用和商业性推广的发生地点有着显着影响，每个区域都存在独特的监管、报销和营运方面的考量，这些因素共同决定了应用的进程。美洲地区聚集了大量的学术研究中心、转化研究所和临床试验活动，从而推动了对发现级测序平台和检验的临床试验检测方法的需求。该地区的临床实验室通常需要在满足监管机构的严格要求的同时，积极争取大型医院系统和专科诊断实验室的早期应用，从而加速从生物标记发现到临床评估的进程。

在欧洲、中东和非洲，监管协调工作和已建立的报销框架正在创造一个环境，​​在这种环境下，检测验证和临床级文件的重要性日益凸显。在一些欧洲市场，公共研究资金和合作研究网络正在支持多中心验证研究，从而提高交叉验证和可重复性。在中东和非洲，对先进诊断和研究基础设施的投资正在涌现，在这些市场中，物流的考量和供应链的韧性往往体现在筹资策略和伙伴关係关係中。

亚太地区兼具大规模生产能力、不断增长的临床研究能力以及对快速发展的分子诊断技术进行投资的医院系统。本地製造地为试剂和耗材的供应提供了保障，而不断壮大的临床定序中心和受託研究机构则扩大了服务的覆盖范围。由于各地区的法律规范存在差异，导致临床应用速度不一，但合作努力和官民合作关係往往能够加速区域检验和商业化进程。了解这些区域差异有助于各组织根据各地区的营运实际情况和临床优先事项，制定伙伴关係、在地化工作和打入市场策略。

深入洞察整合工作流程、策略伙伴关係和检验的服务模式如何为 miRNA 定序和检测市场创造持久优势

miRNA定序和检测生态系统的竞争格局主要围绕着透过整合的工作流程、检验证据和广泛的服务来实现差异化。能够提供从优化的文库建构试剂套件到检验的生物资讯流程等端到端解决方案的仪器和试剂供应商，往往能够降低临床实验室和转化研究团队的实施难度。同时，专业的生物资讯公司则透过提供可重复的小RNA分析流程和可扩展的解读框架来创造价值。

策略伙伴关係和联盟是拓展能力的常用途径。套件生产商与临床实验室之间，或定序中心与製药公司之间的共用，能够实现联合检测方法开发和共享验证研究，从而加速临床合格。同时，临床客户和商业客户之间的竞争凸显了提供强大的客户支援、培训和文件的重要性，这些支援和文件应能证明检测方法的性能和临床效用。围绕检测化学和计算方法的智慧财产权既构成了准入壁垒，也为许可和白牌创造了机会。

卓越的营运能力将使市场领导脱颖而出。投资于品管系统、法规专业知识和透明检验数据的公司，往往能与医院实验室和诊断网络建立更牢固、更值得信赖的关係。此外，提供灵活商业模式的公司，例如订阅式分析、样本特异性定序服务和客製化检测组合开发，将吸引更广泛的终端用户。最终，那些将严格的技术检验与符合临床工作流程和不同医疗系统报销实际情况的服务模式相结合的公司，将获得可持续的竞争优势。

为产业领导者提供切实可行的优先建议，以加快 miRNA倡议。

为了最大限度地提高 miRNA 定序和检测投资的回报，企业领导者应采取一系列策略行动，以提昇技术稳健性、供应链韧性和下游临床整合能力。优先进行严格的检测验证和跨平台一致性研究，以证明其可重复性并推动临床实验室的应用。除了湿实验验证外，还应建立透明、版本控制的生物资讯流程和全面的文檔，以支援监管申报和临床审批流程。

多元化筹资策略，降低突发关税或物流中断的风险，同时在可行的情况下，建立区域性生产或经销伙伴。投资于供应商资质资格确认流程、扩大试剂库存规划，并制定能够保障供应连续性的合约条款。从商业性角度来看，设计模组化产品，将探索性测序与正交验证选项（例如 RT-qPCR 检测和微阵列验证）相结合，使客户能够在统一的框架内完成从研究到临床验证的整个流程。

我们透过培训专案、共用方案以及现场或虚拟侦测设定服务来增强客户能力，从而降低实验室实施的风险。我们积极主动地儘早与临床相关人员、支付方和监管顾问沟通，以明确证据产生路径并降低报销谈判的风险。最后，我们优先考虑资料管治、互通性和安全性，以增强临床医生的信心并支援多中心检验工作。透过将技术严谨性与营运弹性以及以客户为中心的服务设计相结合，各机构可以加速转化医学的进展，并将自身定位为精准医疗计划中值得信赖的合作伙伴。

采用透明的三角验证调查方法，结合一手访谈、技术评估和供应链分析，得出可操作的结论。

本分析所依据的研究整合了多方面的证据，以确保方法的严谨性和实际应用价值。研究人员对价值链上的各相关人员进行了初步的定性访谈，包括分子生物学实验室主任、转化研究人员、委外研发机构负责人。这些访谈有助于了解影响miRNA定序和检测解决方案采用决策的营运限制、检验重点和买方偏好。

除了初步访谈外，技术评估还考察了实验室规程、检测性能文献以及公开的监管指南，以评估方法学的优势和常见失效模式。供应链图谱追踪了试剂和设备采购的关键节点，采购案例研究描述了各组织如何调整采购策略以应对政策和物流压力。竞争格局分析考察了产品系列、服务产品和伙伴关係策略，以识别通用的差异化和价值获取模式。

资料三角测量法整合了定性见解和技术证据，从而对该技术的发展轨迹和应用驱动因素得出确切结论。检验标准尽可能强调可重复性、正交验证路径以及支援临床应用的文件完整性。此方法着重于透明度和可追溯性，记录分析决策的来源和理由，以便读者评估其对自身专案和投资决策的影响。

最终整合着重于检验、协作和营运准备，以此作为将 miRNA 研究成果转化为临床影响的途径。

总之，miRNA定序和检测技术在发现科学和临床应用的交叉领域中占据关键地位。定序平台、检测化学和生物资讯学的进步正在提高小RNA讯号的保真度和可解释性，从而扩大其临床和研究应用范围。然而，要充分发挥miRNA生物标记的潜力，还需要关注检测方法的验证、跨平台一致性以及供应链和法规环境中的实际操作问题。

相关人员若能协调技术研发、监管推广和客户互动方面的投资，将更有利于把发现的讯号转化为临床可操作的检测方法和伴随诊断。同时，切实可行的供应链策略和对本地市场的深入了解，对于帮助企业应对政策变化和特定地区的营运限制至关重要。展望未来，设备供应商、套件製造商、服务供应商和临床合作伙伴之间的协作将推动标准化工作流程和证据包的完善，从而支持更广泛的临床应用。

严格的检验、透明的分析和灵活的服务模式为临床医生和支付方的信任创造了条件。对于致力于精准医疗的机构而言，投资于可重复的miRNA工作流程以及连接发现和临床领域的伙伴关係，将在生物标记开发和患者照护方面带来持久的益处。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的单细胞微型RNA分析平台能够进行详细的细胞异质性分析。
  • 整合人工智慧驱动的生物资讯流程，用于快速解读miRNA表达数据和发现生物标记
  • 拓展细胞外囊泡 miRNA 检测在非侵入性癌症诊断和即时病患监测的应用
  • 开发一种多重数位PCR检测方法，用于临床检体中多种微型RNA的绝对定量。
  • 自动化高通量 miRNA定序工作流程的部署减少了人工操作时间，提高了可重复性。
  • 采用标准化的样品製备套件，以最大限度地减少多个研究实验室间微型RNA NGS结果的偏差。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 miRNA定序与检测市场（依产品类型划分）

  • 表达检测试剂套件
    • 微阵列试剂套件
    • qRT-PCR试剂套件
    • 定序套件
  • 定序平台
  • 服务
    • 生物资讯服务
    • 定序服务

9. miRNA定序和检测市场（按技术划分）

  • 微阵列
  • 次世代定序
  • Rt-Qpcr

第十章 miRNA定序和检测市场（按应用领域划分）

  • 临床诊断
  • 疾病监测
  • 药物发现

第十一章 miRNA定序和检测市场（按最终用户划分）

  • 学术机构
  • 合约研究组织
  • 医院和诊断实验室
  • 製药和生物技术

12. miRNA定序与检测市场（依工作流程划分）

  • 消耗品
    • 套件和试剂
    • 实验室设备
  • 服务
    • 数据分析服务
    • 定序服务

第十三章 miRNA定序和检测市场（按样本类型划分）

  • 血
  • 血清/血浆
  • 组织

第十四章 miRNA定序与检测市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 miRNA定序和检测市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国 miRNA 定序与检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc.
    • Takara Bio Inc.
    • New England Biolabs, Inc.
    • NanoString Technologies, Inc.
    • PerkinElmer, Inc.
Product Code: MRR-0A609A26A984

The miRNA Sequencing & Assay Market is projected to grow by USD 1,127.65 million at a CAGR of 14.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 380.21 million
Estimated Year [2025] USD 435.69 million
Forecast Year [2032] USD 1,127.65 million
CAGR (%) 14.55%

A comprehensive introduction to contemporary miRNA sequencing and assay capabilities that frame scientific potential and translational hurdles for clinical adoption

MicroRNA sequencing and assay science has rapidly matured from a niche research capability into a core element of molecular profiling strategies across translational research and clinical development. Advances in sample processing, library preparation chemistry, and analytical pipelines have increased the reliability of small RNA detection, while parallel improvements in instrumentation have compressed turn-around times and reduced the barrier to routine implementation. As a result, stakeholders across academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies now evaluate miRNA solutions not just as exploratory tools but as candidates for biomarker development, companion diagnostics, and targeted therapeutic discovery.

Despite this progress, the field contends with persistent technical challenges that shape adoption decisions. Low input abundance, sequence similarity among family members, and the presence of isomiRs require highly selective assay design and rigorous quality controls. Moreover, bioinformatics workflows that translate raw reads into actionable signatures remain a differentiator; reproducible alignment, normalization, and annotation strategies determine whether a candidate miRNA achieves translational utility. Regulatory and clinical validation pathways introduce additional complexity, underlining the importance of integrated assays that pair robust wet-lab protocols with validated computational pipelines.

Transitioning from exploratory science to clinical utility calls for coordinated investments in assay standardization, cross-laboratory reproducibility studies, and partnerships that bridge instrument vendors, kit manufacturers, and service providers. In this context, emphasis on interoperable workflows and vendor-agnostic data formats is rising, enabling researchers and clinicians to compare results across platforms and accelerate the translation of miRNA signals into diagnostic and therapeutic insights. Taken together, these dynamics position miRNA sequencing and assay capabilities as pivotal enablers of precision medicine initiatives when implemented with methodological rigor and strategic alignment to clinical goals.

Critical transformative shifts reshaping miRNA sequencing and assay workflows that enable scalable clinical translational pathways and integrated service models

The landscape of miRNA sequencing and assay development is undergoing several transformative shifts that redefine technical expectations and commercial strategies. Next generation sequencing platforms have extended sensitivity and multiplexing capacity, enabling simultaneous profiling of hundreds of small RNAs from reduced sample inputs, which in turn drives new use cases in longitudinal monitoring and minimally invasive sampling. Concurrently, improvements in assay chemistry and library preparation have reduced bias and increased uniformity across sequencing runs, making cross-study comparison increasingly feasible and fueling broader interest from clinical research programs.

At the same time, the convergence of RT-qPCR, microarray, and sequencing approaches has created a tiered diagnostics ecosystem in which high-throughput discovery via sequencing is complemented by targeted validation using qRT-PCR assays or microarray panels. This multi-modal pathway supports rigorous biomarker qualification: discovery, orthogonal validation, and then deployment in a regulated clinical testing environment. Alongside wet-lab evolution, bioinformatics and machine learning algorithms have matured to handle small-RNA specific challenges, including isomiR detection, sequence trimming artifacts, and cross-platform normalization, thereby enhancing confidence in derived signatures.

Operational shifts are also evident. Service providers are expanding offerings to include end-to-end solutions that combine sample logistics, sequencing execution, and interpretive analytics, while instrument and reagent manufacturers prioritize integrated workflows that improve ease of adoption for clinical labs. Policy and payer discourse is increasingly focused on evidentiary standards for molecular biomarkers, prompting closer collaboration among assay developers, clinical laboratories, and regulatory bodies to establish validation templates and performance benchmarks. Taken together, these shifts are moving miRNA assays from experimental workflows toward standardized components of precision medicine pipelines.

How evolving tariff dynamics have reshaped supply-chain strategy, procurement practices, and resiliency planning across miRNA sequencing and assay operations

Recent trade policy adjustments have introduced an additional layer of complexity into procurement planning, supply-chain design, and cost management for organizations that rely on imported instruments, consumables, and reagents. Tariff actions affecting imported laboratory equipment and reagents have increased the effective landed cost for many market participants, prompting procurement teams to reassess vendor relationships, contract terms, and inventory strategies. In response, some organizations have accelerated efforts to diversify suppliers and source critical inputs from geographically closer manufacturers to mitigate exposure to cross-border policy shifts.

These dynamics have material operational consequences. Research institutions and clinical laboratories are adapting purchasing cadences, increasing buffer stocks of essential reagents, and extending supplier qualification processes to include alternative domestic and regional partners. Manufacturers and distributors, for their part, are exploring localized assembly, alternative logistics routing, and restructured pricing models to preserve customer access while managing margin pressures. Service providers that operate international sequencing centers are likewise evaluating where to locate capacity and how to structure customer pricing to reflect added duty and compliance costs.

Over time, sustained tariff pressures often catalyze investment in regional manufacturing capabilities and in strategic partnerships that reduce dependency on a single supply base. At the same time, procurement professionals and R&D leaders must weigh the trade-offs between supply resilience and the technical performance of alternative components. Continuing to monitor policy developments and proactively engaging with suppliers to understand inventory pipelines, lead times, and contingency arrangements will remain essential to maintain operational continuity and protect timelines for miRNA assay development and clinical validation.

Comprehensive segmentation insights that align product types, technologies, applications, workflows, end users, and sample type considerations to inform strategic investment

Interpreting the market requires attention to multiple segmentation vectors that collectively define product design, adoption pathways, and user requirements. Based on product type, stakeholders must evaluate Expression Assay Kit options that include microarray kits, qRT-PCR kits, and sequencing kits alongside sequencing platforms and a range of services that span bioinformatics services and sequencing services. Each product class demands distinct validation standards and support models: microarray and qRT-PCR kits are often optimized for targeted panels and clinical throughput, whereas sequencing kits and platforms favor discovery breadth and multiplex capacity. Services that provide bioinformatics and sequencing execution bridge the gap between raw data generation and actionable interpretation.

Technology segmentation highlights the co-existence of microarray, next generation sequencing, and RT-qPCR approaches, each providing a different balance of throughput, sensitivity, and cost per sample. Microarray solutions remain valuable for standardized panels and comparative studies, RT-qPCR is the workhorse for targeted validation and clinical assay confirmation, and next generation sequencing delivers comprehensive discovery and isoform-level resolution that supports research and novel biomarker identification.

When viewed through the lens of application, clinical diagnostics, disease research, and drug discovery each place unique demands on assay performance, regulatory documentation, and longitudinal reproducibility. End users including academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies require differentiated support: academic teams favor openness and flexible protocols for exploratory work, CROs emphasize throughput and standardized reporting, clinical labs prioritize validated kits and compliance documentation, and industry sponsors focus on integration with clinical trial workflows.

Workflow segmentation divides offerings into consumables and services, where consumables include kits and reagents as well as labware and services encompass data analysis services and sequencing services. Consumable quality and batch consistency strongly influence downstream data reliability, while services that deliver sophisticated analytics are increasingly critical to translate complex small-RNA profiles into clinically meaningful readouts. Sample type further nuances product selection and protocol design; assays optimized for blood, serum/plasma, or tissue must address distinct pre-analytical variables such as RNA yield, degradation profiles, and matrix effects. Taken together, these segmentation perspectives frame where investments in assay optimization, regulatory strategy, and customer support will deliver the greatest return in adoption and impact.

Actionable regional insights that map innovation hubs, regulatory expectations, and operational realities across the Americas, EMEA, and Asia-Pacific regions

Regional dynamics strongly influence where innovation, clinical translation, and commercial traction occur, and each geography presents distinct regulatory, reimbursement, and operational considerations that shape adoption timelines. In the Americas, a concentration of academic research centers, translational institutes, and clinical trial activity drives demand for both discovery-grade sequencing platforms and validated assays for clinical studies. Clinical laboratories in this region often balance stringent regulatory expectations with early adoption by leading hospital systems and specialist diagnostic labs, which accelerates the pathway from biomarker discovery to clinical evaluation.

Across Europe, Middle East & Africa, regulatory harmonization efforts and established reimbursement frameworks create a landscape where assay validation and clinical-grade documentation receive pronounced emphasis. Public research funding and collaborative networks in several European markets support multi-center validation studies that enhance cross-validation and reproducibility. In the Middle East and Africa, pockets of investment in advanced diagnostics and research infrastructure are emerging; however, logistical considerations and supply-chain resilience often inform procurement strategies and partnerships in these markets.

The Asia-Pacific region is notable for a mix of high-volume manufacturing capacity, growing clinical research capabilities, and rapidly expanding hospital systems that are investing in molecular diagnostics. Local manufacturing hubs support reagent and consumable supply, while a growing base of clinical sequencing centers and contract research organizations expands service availability. Regulatory frameworks across the region vary, creating heterogeneity in clinical adoption speed, yet collaborative initiatives and public-private partnerships frequently accelerate localized validation and commercialization. Understanding these regional contrasts helps organizations tailor partnerships, localization efforts, and go-to-market strategies to the operational realities and clinical priorities of each geography.

Key competitive insights into how integrated workflows, strategic partnerships, and validated service models create durable advantages in miRNA sequencing and assay markets

Competitive dynamics in the miRNA sequencing and assay ecosystem center on differentiation through integrated workflows, validation evidence, and service breadth. Instrument and reagent suppliers that offer end-to-end solutions, from optimized library kits to validated bioinformatics pipelines, tend to reduce implementation friction for clinical laboratories and translational research teams. Service providers that combine sequencing capacity with domain-specific analytics create compelling value propositions for sponsors seeking turnkey biomarker programs, while specialized bioinformatics firms add value by delivering reproducible small-RNA pipelines and scalable interpretation frameworks.

Strategic partnerships and collaborations are a prevalent route to capability expansion. Alliances between kit manufacturers and clinical laboratories, or between sequencing centers and pharmaceutical sponsors, enable co-development of assays and shared validation studies that accelerate clinical qualification. At the same time, competition for clinical and commercial customers emphasizes the need for robust customer support, training, and documentation that demonstrate assay performance and clinical utility. Intellectual property around assay chemistry and computational methods can create barriers to entry but also opportunities for licensing and white-label offerings.

Operational excellence differentiates market leaders. Firms that invest in quality management systems, regulatory affairs expertise, and transparent validation data tend to build greater trust with hospital laboratories and diagnostic networks. Additionally, companies that offer flexible commercial models, including subscription analytics, per-sample sequencing services, and bespoke panel development, appeal to a broader set of end users. Ultimately, sustained competitive advantage will accrue to organizations that combine rigorous technical validation with service models that align to clinical workflows and the reimbursement realities of diverse health systems.

Practical and prioritized recommendations for industry leaders to fast-track assay validation, supply resilience, and clinical integration for miRNA initiatives

Leaders seeking to maximize the impact of miRNA sequencing and assay investments should pursue a coordinated set of strategic actions that address technical robustness, supply-chain resilience, and downstream clinical integration. Prioritize rigorous assay validation and cross-platform concordance studies to demonstrate reproducibility and to facilitate adoption by clinical laboratories. Complement wet-lab validation with transparent, version-controlled bioinformatics pipelines and comprehensive documentation that support regulatory submissions and clinical accreditation processes.

Diversify sourcing strategies to reduce exposure to sudden tariff or logistics disruptions, while simultaneously cultivating regional manufacturing or distribution partnerships where feasible. Invest in supplier qualification processes, extended reagent inventory planning, and contractual terms that support continuity of supply. From a commercial perspective, design modular offerings that couple discovery sequencing with orthogonal validation options such as RT-qPCR panels or microarray confirmations, enabling customers to progress from research to clinical validation within a coherent framework.

Strengthen customer enablement through training programs, shared protocols, and on-site or virtual assay setup services that reduce implementation risk for laboratories. Engage early and proactively with clinical stakeholders, payers, and regulatory advisors to articulate evidence generation pathways and to de-risk reimbursement conversations. Finally, prioritize data governance, interoperability, and security to foster clinician trust and to support multi-center validation efforts. By aligning technical rigor with operational resilience and customer-centric service design, organizations can accelerate translational progress and position themselves as trusted partners in precision medicine initiatives.

A transparent, triangulated research methodology combining primary interviews, technical assessments, and supply-chain analysis to support actionable conclusions

The research underpinning this analysis combined multiple evidence streams to ensure methodological rigor and practical relevance. Primary qualitative interviews were conducted with stakeholders across the value chain, including molecular laboratory directors, translational researchers, procurement leads, and leaders of contract research organizations. These conversations informed an understanding of operational constraints, validation priorities, and buyer preferences that shape adoption decisions for miRNA sequencing and assay solutions.

Complementing primary interviews, technical assessments reviewed laboratory protocols, assay performance literature, and publicly available regulatory guidance to evaluate methodological strengths and common failure modes. Supply-chain mapping exercises traced key nodes for reagent and instrument availability, while procurement case studies illustrated how organizations adapt purchasing strategies in response to policy or logistics pressures. Competitive landscape analysis examined product portfolios, service offerings, and partnership strategies to identify common patterns of differentiation and value capture.

Data triangulation methods synthesized qualitative insights with technical evidence, enabling robust conclusions about technology trajectories and adoption levers. Wherever feasible, validation criteria emphasized reproducibility, orthogonal confirmation pathways, and the completeness of documentation that supports clinical use. The methodology focused on transparency and traceability, documenting sources and rationale for analytical judgments so that readers can assess implications for their own programs and investment decisions.

A conclusive synthesis emphasizing validation, collaboration, and operational readiness as the pathway to transform miRNA insights into clinical impact

In sum, miRNA sequencing and assay capabilities occupy a pivotal position at the intersection of discovery science and clinical translation. Advances in sequencing platforms, assay chemistries, and bioinformatics have collectively improved the fidelity and interpretability of small-RNA signals, expanding the range of viable clinical and research applications. Yet realizing the full potential of miRNA biomarkers requires disciplined attention to assay validation, cross-platform concordance, and the operational realities of supply chains and regulatory environments.

Stakeholders that align investments across technical development, regulatory engagement, and customer enablement will be best positioned to convert discovery-stage signals into clinically actionable tests and therapeutic companion diagnostics. At the same time, pragmatic supply-chain strategies and regional market understanding will prove critical as organizations navigate policy shifts and localized operational constraints. Moving forward, collaboration among instrument suppliers, kit manufacturers, service providers, and clinical partners will accelerate maturation of standardized workflows and evidence packages that support broader clinical adoption.

The path from characterization to clinical impact is iterative: rigorous validation, transparent analytics, and responsive service models create the conditions for trust among clinicians and payers. For organizations focused on precision medicine, investing in reproducible miRNA workflows and in partnerships that bridge discovery and clinical practice will yield durable benefits in biomarker development and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of single-cell microRNA profiling platforms enabling detailed cellular heterogeneity analysis
  • 5.2. Integration of AI-driven bioinformatics pipelines for rapid miRNA expression data interpretation and biomarker discovery
  • 5.3. Expansion of extracellular vesicle miRNA assay applications for non-invasive cancer diagnostics and real-time patient monitoring
  • 5.4. Development of multiplexed digital PCR assays for absolute quantification of diverse microRNAs in clinical specimens
  • 5.5. Rollout of automated high-throughput miRNA sequencing workflows reducing hands-on time and enhancing reproducibility
  • 5.6. Adoption of standardized library preparation kits to minimize biases in microRNA NGS results across multiple research laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. miRNA Sequencing & Assay Market, by Product Type

  • 8.1. Expression Assay Kit
    • 8.1.1. Microarray Kit
    • 8.1.2. Qrt-Pcr Kit
    • 8.1.3. Sequencing Kit
  • 8.2. Sequencing Platform
  • 8.3. Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Sequencing Services

9. miRNA Sequencing & Assay Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
  • 9.3. Rt-Qpcr

10. miRNA Sequencing & Assay Market, by Application

  • 10.1. Clinical Diagnostics
  • 10.2. Disease Research
  • 10.3. Drug Discovery

11. miRNA Sequencing & Assay Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotech

12. miRNA Sequencing & Assay Market, by Workflow

  • 12.1. Consumables
    • 12.1.1. Kits & Reagents
    • 12.1.2. Labware
  • 12.2. Services
    • 12.2.1. Data Analysis Services
    • 12.2.2. Sequencing Services

13. miRNA Sequencing & Assay Market, by Sample Type

  • 13.1. Blood
  • 13.2. Serum/Plasma
  • 13.3. Tissue

14. miRNA Sequencing & Assay Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. miRNA Sequencing & Assay Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. miRNA Sequencing & Assay Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Illumina, Inc.
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. QIAGEN N.V.
    • 17.3.4. Agilent Technologies, Inc.
    • 17.3.5. F. Hoffmann-La Roche Ltd
    • 17.3.6. Bio-Rad Laboratories, Inc.
    • 17.3.7. Takara Bio Inc.
    • 17.3.8. New England Biolabs, Inc.
    • 17.3.9. NanoString Technologies, Inc.
    • 17.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MIRNA SEQUENCING & ASSAY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MIRNA SEQUENCING & ASSAY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MIRNA SEQUENCING & ASSAY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOL